Intravacc, a global contract development and manufacturing organisation (CDMO) and Primrose Bio, a biotechnology company, have recently announced a strategic partnership to enhance the development and supply of conjugate vaccines.
Third parties engaged in developing conjugate vaccines will have access to a solution for vaccine conjugation, manufacturing and supply.
Dr. Helge Zieler, Primrose Bio’s CEO, further comments: “Expanding the capability of our PeliCRM197 franchise with Intravacc now creates a full-service solution for our early-stage customers and partners needing vaccine conjugation development. With both companies having direct product experience in preclinical, manufacturing and clinical development, the combined know-how of the two firms fills a gap that is needed by the vaccine industry as a whole."
This partnership harnesses the synergistic strengths of both companies, fostering innovation and efficiency in vaccine development.
Intravacc contributes its technical expertise, updated facilities and robust capabilities in antigen conjugation process development, scale-up and GMP production of conjugate vaccines.
Primrose Bio complements this with its ultra-pure production, supply chain and regulatory support for the PeliCRM197 carrier protein, a vital ingredient in conjugate vaccine formulations and the only commercial CRM197 used in commercial vaccines available for purchase.
This carrier protein is offered in a range of quantities and grades, from milligrams to kilograms, both for research and GMP applications. The partnership signifies a strategic alignment aimed at advancing vaccine development and accessibility for researchers and industry clients.
